Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INCR -- Incara Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (163)	5/2/2002 9:32:04 PM
From: mopgcw	Read Replies (1) \| Respond to of 196

Incara to Discuss Clinical Trial Plans for Liver Cell Therapy at Stem Cell and Regenerative Medicine Roundtable RESEARCH TRIANGLE PARK, N.C., May 2 /PRNewswire-FirstCall/ -- Incara Pharmaceuticals Corporation (Nasdaq: INCR) President and CEO, Clayton I. Duncan, will discuss Incara's clinical trial plans for liver cell therapy as an invited participant in a Stem Cell and Regenerative Medicine Roundtable. The Roundtable will be part of the Second Annual Biotechnology Industry Conference sponsored by The Wall Street Transcript. ( www.twst.com/conferences/bio2002/ bio2002.html ) The conference will be held in New York City on May 9, 2002 and will feature financial experts from the biotech sector and CEOs of leading-edge biotech companies. Incara is currently preparing an IND to be filed with the FDA to begin initial Phase 1 clinical trials for the transplantation of human liver cells as a treatment for adults with end-stage liver diseases. Incara's cell population is a well-characterized mixture of liver cells that contains hepatic stem cells. This year approximately 30,000 people in the United States will die from chronic liver disease. Although decades of research have led to a better understanding of diseases that affect the liver, the only cure for many of these diseases is a liver transplant. There are only about 5,000 transplantable donor livers available in the United States each year while there are approximately 18,000 patients currently on waiting lists for a liver transplant. The incidence of chronic liver failure is expected to increase over the next 10 years as a result of the "silent epidemic" of hepatitis C. The NIH estimates that up to four million people in the U.S. have been infected with this virus and researchers project that over the next 10 years, approximately 15% of these people will develop cirrhosis. Incara believes that cell therapy offers promise to patients afflicted with devastating liver diseases. Incara Pharmaceuticals Corporation (www.incara.com) is focused on disease therapies based on tissue protection, repair and regeneration. In particular, the company is developing cell therapy for treatment of liver failure. Incara is also developing a series of catalytic antioxidants as treatments for protection of cells from damage occurring in stroke and cancer radiation therapy, and for protection of cells from transplant rejection. In addition, Incara is conducting a Phase 2/3 multicenter clinical trial for deligoparin, an ultra-low molecular weight heparin being developed with Elan Corporation for treatment of ulcerative colitis.